Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff

Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With the trials overrunning by months, the biotech is laying off 30% of its employees—including some senior managers—and focusing all its efforts on its lead program. One year ago, the company expected to have data from the first phase 3 trial of its COMP360 psilocybin […]